STOCK TITAN
  1. Home
  2. News
  3. FULC

Fulcrum Therapeutics Inc - FULC STOCK NEWS

Welcome to our dedicated news page for Fulcrum Therapeutics (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fulcrum Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fulcrum Therapeutics's position in the market.

News
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
Rhea-AI Summary
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024. The Company focuses on developing small molecules for rare genetic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fulcrum Therapeutics, Inc. granted non-statutory stock options to its new chief medical officer, Dr. Patrick Horn, to purchase 400,000 shares of common stock at an exercise price of $10.12 per share. The options have a ten-year term and vest over four years, aligning with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
News
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Rhea-AI Summary
Fulcrum Therapeutics appoints Dr. Patrick Horn as Chief Medical Officer, bringing over 20 years of rare disease drug development experience. Dr. Horn will lead clinical development for losmapimod and pociredir programs, aiming for regulatory approvals and commercial launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.92%
Tags
management
News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fulcrum Therapeutics, Inc. granted non-statutory stock options to two new employees under the 2022 Inducement Stock Incentive Plan. The employees received a total of 85,600 options to purchase shares of the company's common stock at $11.33 per share, with a ten-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) will present a corporate overview at the Leerink Partners Global Biopharma Conference. The company focuses on developing small molecules for rare genetic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
conferences
-
News
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
Rhea-AI Summary
Fulcrum Therapeutics, Inc. reports financial results for Q4 2023, updates on Phase 3 REACH trial of losmapimod in FSHD, and restarts Phase 1b PIONEER trial of pociredir in SCD. Cash position improved to $236.2 million. Collaboration revenue increased in Q4 2023. R&D expenses slightly up. Net loss decreased. Cash runway expected till 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
earnings
News
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
Rhea-AI Summary
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) will release its Q4 and full year 2023 financial results on Feb. 27, 2024. A conference call and webcast will be held to discuss the results and recent corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences earnings
-
News
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Fulcrum Therapeutics, Inc. will present a corporate overview at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The webcast of the presentation will be accessible on the company's website. The management will also participate in one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
-
News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) grants non-statutory stock options to new employees, totaling 240,500 options at an exercise price of $5.20 per share, with a ten-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced the granting of non-statutory stock options to a new employee as an inducement to join the company. The options, totaling 58,760 shares, were granted at an exercise price of $3.59 per share, with a ten-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock FULC logo
Fulcrum Therapeutics Inc

Nasdaq:FULC

FULC Rankings

#3053 Ranked by Market Cap
#4442 Ranked by Stock Gains
N/A Ranked by Dividends

FULC Stock Data

464.51M
38.46M
1.38%
99.44%
3.65%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cambridge

About FULC

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng